SSTR5
Somatostatin Receptor 5: A Key Regulator of Hormone Secretion and Therapeutic Target in Neuroendocrine Disorders
Gene Information Card
| Symbol | SSTR5 |
|---|---|
| Full Name | Somatostatin Receptor 5 |
| Gene Type | protein-coding |
| Chromosomal Location | 16p13.3 |
| NCBI Gene ID | 6755 ncbi.nlm.nih.gov/gene/6755 |
| Ensembl ID | ENSG00000162073 |
| UniProt ID | P35346 |
| OMIM ID | 182455 |
| HGNC ID | 11334 |
| Aliases | SS-5-R, SST5, somatostatin receptor subtype 5 |
Description
SSTR5 encodes a G protein-coupled receptor for somatostatin, a peptide hormone that inhibits the release of growth hormone, insulin, glucagon, and other hormones. SSTR5 is predominantly expressed in the pituitary gland, pancreas, and gastrointestinal tract. It mediates somatostatin's inhibitory effects on hormone secretion and cell proliferation. The receptor is a key therapeutic target for somatostatin analogs used in acromegaly, Cushing disease, and neuroendocrine tumors.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Acromegaly | SSTR5 activation by somatostatin analogs suppresses growth hormone secretion from pituitary adenomas; reduced SSTR5 expression correlates with treatment resistance. | PMID: 25636053, ClinVar |
| Cushing Disease | SSTR5 is the predominant somatostatin receptor subtype in corticotroph adenomas; pasireotide, a multi-receptor somatostatin analog with high SSTR5 affinity, reduces ACTH secretion. | PMID: 22535969, ClinVar |
| Neuroendocrine Tumors (NETs) | SSTR5 overexpression in NETs enables imaging and targeted therapy with radiolabeled somatostatin analogs (e.g., 177Lu-DOTATATE). | PMID: 28289288, COSMIC |
| Pituitary Adenoma | Somatic mutations and altered SSTR5 expression contribute to tumor growth and hormone hypersecretion. | PMID: 30093543, COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Pituitary | 12.5 | High |
| Pancreas | 8.3 | Medium |
| Small Intestine | 6.1 | Medium |
| Stomach | 4.7 | Low |
| Adrenal Gland | 3.2 | Low |
| Brain (Cerebellum) | 2.1 | Low |
| Liver | 0.5 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| BON-1 (carcinoid) | 15.2 | High expression; used in NET research |
| QGP-1 (pancreatic NET) | 11.8 | High expression; somatostatin analog response model |
| NCI-H727 (lung carcinoid) | 9.4 | Moderate expression |
| HEK293 | 0.3 | Low endogenous; used for recombinant expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.100G>A (p.Gly34Arg) | Missense | <0.1% | Reduced cell surface expression and signaling; associated with pituitary adenoma |
| c.215C>T (p.Pro72Leu) | Missense | <0.1% | Altered ligand binding affinity; reported in acromegaly |
| c.776A>G (p.Tyr259Cys) | Missense | <0.1% | Impaired receptor internalization; functional impact unclear |
Mutation functional classification
Loss of Function (LOF)
Mutations such as p.Gly34Arg reduce receptor expression and signaling, leading to diminished somatostatin response and potential hormone hypersecretion.
Gain of Function (GOF)
No well-characterized gain-of-function mutations reported in SSTR5.
Dominant Negative (DN)
No dominant-negative mutations described for SSTR5.
View complete mutation data：
Gene Ontology (GO)
| • G protein-coupled receptor activity | • somatostatin receptor activity |
| • adenylate cyclase inhibiting G protein-coupled receptor signaling pathway | • negative regulation of cell population proliferation |
| • negative regulation of hormone secretion | • neuroendocrine cell differentiation |
| • plasma membrane |
Pathways
• Somatostatin signaling pathway
• GPCR downstream signaling
• cAMP inhibition pathway
• Neuroendocrine tumor signaling
Protein Summary
SSTR5 is a 364-amino acid G protein-coupled receptor with seven transmembrane domains. It binds somatostatin-14 and somatostatin-28 with high affinity. Upon activation, it couples to Gi/o proteins to inhibit adenylate cyclase, reduce cAMP levels, and modulate ion channels. SSTR5 also activates MAPK and PI3K pathways, influencing cell growth and apoptosis. The receptor undergoes agonist-induced internalization and desensitization. Its expression is regulated by transcription factors including POU1F1 and GATA-2.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SSTR5 Knockout HEK293 Cell Line | EDJ-KQ1792 | Human | 6755 | Details Get a Quote |
| SSTR5 Knockout HCT 116 Cell Line | EDJ-KQ21653 | Human | 6755 | Details Get a Quote |
| SSTR5 Knockout HeLa Cell Line | EDJ-KQ54574 | Human | 6755 | Details Get a Quote |
| SSTR5 Knockout A-549 Cell Line | EDJ-KQ63059 | Human | 6755 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
